Download the FAQ

Bringing you the most up to date news from the international Duchenne community is one of our core aims. 

Action Duchenne and Parent Project Muscular Dystrophy (PPMD) co-moderated a Webinar to discuss Summit's recently reported positive interim 24-week data from PhaseOut DMD.

The webinar generated a lot of interest with many people in attendance; but if you missed out, a recording of the webinar is available above.

Jon Tinsley (Chief Scientific Officer) and Ann Heatherington (Head of Clinical Development) from Summit, were kind enough to talk us through their results to date.

Action Duchenne, PPMD and Summit Therapeutics have worked together to bring you a handy FAQ document to help explain things as well.

Thank you to PPMD and Summit Therapeutics for their help.